A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer’s disease

INTRODUCTION: Because of its genetic underpinnings and consistent age of onset within families, autosomal dominant Alzheimer’s disease (ADAD) provides a unique opportunity to conduct clinical trials of investigational agents as preventative or symptom-delaying treatments. The design of such trials m...

Descripción completa

Detalles Bibliográficos
Autores principales: Grill, Joshua D., Bateman, Randall J., Buckles, Virginia, Oliver, Angela, Morris, John C., Masters, Colin L., Klunk, William E., Ringman, John M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4511231/
https://www.ncbi.nlm.nih.gov/pubmed/26203303
http://dx.doi.org/10.1186/s13195-015-0135-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4511231/
https://www.ncbi.nlm.nih.gov/pubmed/26203303
http://dx.doi.org/10.1186/s13195-015-0135-0

Ejemplares similares